| アブストラクト | INTRODUCTION: Topical corticosteroid (TCS) phobia, which tends to interfere with the continuation of TCS treatment for atopic dermatitis (AD), has not been elucidated in Japan using the topical corticosteroid phobia (TOPICOP) scale. We aimed to clarify TCS phobia among patients with AD in Japan and evaluate its relationship with AD conditions. METHODS: This observational study, using the database of health receipt (between October 2021 and October 2022) and online questionnaire (conducted in October 2022) data, included adult respondents with and without AD and caregivers who responded to the questionnaire about their children aged </= 18 years, with and without AD. The TOPICOP scores measuring TCS phobia were summarized and compared according to AD severity, consultation with a doctor, and presence of AD using an analysis of covariance (ANCOVA) model (covariates: sex and age). RESULTS: In this study, 1507 adults with AD and 525 caregivers of children with AD were included. Among adults with AD, the mean TOPICOP score (+/- standard deviation) was 42.5 +/- 18.9, while it was 41.7 +/- 18.6 among caregivers of children with AD. Of the three TOPICOP domains (knowledge and beliefs, fears, and behaviors), the fear domain questions showed the highest percentage of agreement in both adults and caregivers of children with AD. In the ANCOVA models, the scores did not differ significantly according to AD severity, consultation with a doctor, or the presence of AD in adults and caregivers but significantly differed by sex and age (both p < 0.001) in adults. CONCLUSION: We obtained the latest TOPICOP scores that were independent of AD conditions in Japan. Most adults and caregivers of children with AD had TCS phobia, regardless of the AD conditions. Periodic education may be required for a wide range of patients and caregivers to ease TCS phobia and enable them to continue appropriate AD treatment. |
|---|
| 投稿者 | Nakahara, Takeshi; Murota, Hiroyuki; Noto, Shinichi; Matsukawa, Miyuki; Toda, Rikiya; Konishi, Yasuhito; Michikami, Daisaku |
|---|
| 組織名 | Department of Dermatology, Graduate School of Medical Sciences, Kyushu;University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan.;Department of Dermatology, Graduate School of Biomedical Sciences, Nagasaki;University, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.;Department of Rehabilitation, Niigata University of Health and Welfare, 1398;Shimamicho, Kita-ku, Niigata City, Niigata, 950-3198, Japan.;Medical Affairs, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka,;540-0021, Japan. Matsukawa.Miyuki@otsuka.jp.;Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Shinagawa Grand Central Tower,;2-16-4 Konan, Minato-ku, Tokyo, 108-8241, Japan. |
|---|
